BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 33728448)

  • 21. Cutaneous extranodal natural killer/T-cell lymphoma: a comparative clinicohistopathologic and survival outcome analysis of 45 cases according to the primary tumor site.
    Lee WJ; Jung JM; Won CH; Chang SE; Choi JH; Chan Moon K; Park CS; Huh J; Lee MW
    J Am Acad Dermatol; 2014 Jun; 70(6):1002-9. PubMed ID: 24629518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Both c-Myc and Ki-67 expression are predictive markers in patients with extranodal NK/T-cell lymphoma, nasal type: a retrospective study in China.
    Huang X; Sun Q; Fu H; Zhou X; Guan X; Wang J
    Pathol Res Pract; 2014 Jun; 210(6):351-6. PubMed ID: 24642368
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical significance of serum soluble interleukin-2 receptor-α in extranodal natural killer/T-cell lymphoma (ENKTL): a predictive biomarker for treatment efficacy and valuable prognostic factor.
    Wang L; Liao DZ; Zhang J; Xia ZJ; Peng XW; Lu Y
    Med Oncol; 2013 Dec; 30(4):723. PubMed ID: 24037346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Long-term effect of risk-adaptive therapy for early stage extranodal NK/T cell lymphoma].
    Wu T; Liu QL; Hu YF; Zhang J; Chen MX; Chen XX; Huang YH; Lu B
    Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):859-864. PubMed ID: 31770855
    [No Abstract]   [Full Text] [Related]  

  • 25. High C-Reactive Protein to Albumin Ratio Predicts Inferior Clinical Outcomes in Extranodal Natural Killer T-Cell Lymphoma.
    Di QS; Xu T; Song Y; Zuo ZG; Cao FJ; Yu XJ; Tang JY; Zhang W; Li C; Wan GX; Cai XJ
    Dose Response; 2020; 18(2):1559325820917824. PubMed ID: 32284703
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Body mass index as a prognostic factor in patients with extranodal natural killer/T-cell lymphoma, nasal type.
    Liu J; Deng YT; Zhang L; Li N; Jiang M; Zou LQ; Jiang Y
    Oncotarget; 2016 Nov; 7(47):78159-78167. PubMed ID: 27556299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extranodal NK/T-cell lymphoma, nasal type: Clinical features, outcome, and prognostic factors in 101 cases.
    Su YJ; Wang PN; Chang H; Shih LY; Lin TL; Kuo MC; Chuang WY; Wu JH; Tang TC; Hung YS; Dunn P; Kao HW
    Eur J Haematol; 2018 Sep; 101(3):379-388. PubMed ID: 29908084
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes of patients treated with SVILE
    Wei L; Yang L; Ye J; Cong J; Li X; Yao N; Yang J; Cui X; Ding J; Wu Y; Wang J
    Cancer Biol Med; 2020 Aug; 17(3):795-804. PubMed ID: 32944407
    [No Abstract]   [Full Text] [Related]  

  • 29. CD30 expression in extranodal natural killer/T-cell lymphoma, nasal type among 622 cases of mature T-cell and natural killer-cell lymphoma at a single institution in South China.
    Feng Y; Rao H; Lei Y; Huang Y; Wang F; Zhang Y; Xi S; Wu Q; Shao J
    Chin J Cancer; 2017 May; 36(1):43. PubMed ID: 28486951
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extranodal natural killer/T-Cell lymphoma: A population-based comparison of sinonasal and extranasal disease.
    Vazquez A; Khan MN; Blake DM; Sanghvi S; Baredes S; Eloy JA
    Laryngoscope; 2014 Apr; 124(4):888-95. PubMed ID: 24114591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis.
    Kim SJ; Yoon DH; Jaccard A; Chng WJ; Lim ST; Hong H; Park Y; Chang KM; Maeda Y; Ishida F; Shin DY; Kim JS; Jeong SH; Yang DH; Jo JC; Lee GW; Choi CW; Lee WS; Chen TY; Kim K; Jung SH; Murayama T; Oki Y; Advani R; d'Amore F; Schmitz N; Suh C; Suzuki R; Kwong YL; Lin TY; Kim WS
    Lancet Oncol; 2016 Mar; 17(3):389-400. PubMed ID: 26873565
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project.
    Fox CP; Civallero M; Ko YH; Manni M; Skrypets T; Pileri S; Kim SJ; Cabrera ME; Shustov AR; Chiattone CS; Horwitz SM; Dlouhy I; Spina M; Hitz F; Montoto S; Nagler A; Martinez V; De Souza CA; Fernandez-Alvarez R; Ballova V; Gabús R; Inghirami G; Federico M; Kim WS
    Lancet Haematol; 2020 Apr; 7(4):e284-e294. PubMed ID: 32105608
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Roles of Radiotherapy and Chemotherapy in the Era of Multimodal Treatment for Early-Stage Nasal-Type Extranodal Natural Killer/T-Cell Lymphoma.
    Kim TH; Kim JS; Suh YG; Cho J; Yang WI; Suh CO
    Yonsei Med J; 2016 Jul; 57(4):846-54. PubMed ID: 27189276
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High IL-6 expression in the tumor microenvironment is associated with poor prognosis of patients with extranodal natural / killer T-cell lymphoma (ENKTL).
    Rong Q; Gao Y; Cai Q; Wang X; Bai B; Ping L; He H; Rao H; Zhang Y; Li Z; Cai Q; Jiang W; Huang H
    Expert Rev Anticancer Ther; 2021 Jan; 21(1):121-127. PubMed ID: 33397158
    [No Abstract]   [Full Text] [Related]  

  • 35. 18F-FDG PET/CT for Prognostic Stratification of Patients With Extranodal Natural Killer/T-Cell Lymphoma.
    Qin C; Yang S; Sun X; Xia X; Li C; Lan X
    Clin Nucl Med; 2019 Mar; 44(3):201-208. PubMed ID: 30624268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A gene-expression-based signature predicts survival in adults with T-cell lymphoblastic lymphoma: a multicenter study.
    Tian XP; Xie D; Huang WJ; Ma SY; Wang L; Liu YH; Zhang X; Huang HQ; Lin TY; Rao HL; Li M; Liu F; Zhang F; Zhong LY; Liang L; Lan XL; Li J; Liao B; Li ZH; Tang QL; Liang Q; Shao CK; Zhai QL; Cheng RF; Sun Q; Ru K; Gu X; Lin XN; Yi K; Shuang YR; Chen XD; Dong W; Sang W; Sun C; Liu H; Zhu ZG; Rao J; Guo QN; Zhou Y; Meng XL; Zhu Y; Hu CL; Jiang YR; Zhang Y; Gao HY; He WJ; Xia ZJ; Pan XY; Lan H; Li GW; Liu L; Bao HZ; Song LY; Kang TB; Cai QQ
    Leukemia; 2020 Sep; 34(9):2392-2404. PubMed ID: 32080345
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis.
    Kim SJ; Choi JY; Hyun SH; Ki CS; Oh D; Ahn YC; Ko YH; Choi S; Jung SH; Khong PL; Tang T; Yan X; Lim ST; Kwong YL; Kim WS;
    Lancet Haematol; 2015 Feb; 2(2):e66-74. PubMed ID: 26687611
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic performance and prognostic value of circulating tumor DNA methylation marker in extranodal natural killer/T cell lymphoma.
    Tian XP; Zhang YC; Lin NJ; Wang L; Li ZH; Guo HG; Ma SY; An MJ; Yang J; Hong YH; Wang XH; Zhou H; Li YJ; Rao HL; Li M; Hu SX; Lin TY; Li ZM; Huang H; Liang Y; Xia ZJ; Lv Y; Liu YY; Duan ZH; Chen QY; Wang JN; Cai J; Xie Y; Ong CK; Liu F; Liu YY; Yan Z; Huang L; Tao R; Li WY; Huang HQ; Cai QQ
    Cell Rep Med; 2023 Feb; 4(2):100859. PubMed ID: 36812892
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fasting blood glucose is a novel prognostic indicator for extranodal natural killer/T-cell lymphoma, nasal type.
    Cai Q; Luo X; Liang Y; Rao H; Fang X; Jiang W; Lin T; Lin T; Huang H
    Br J Cancer; 2013 Feb; 108(2):380-6. PubMed ID: 23299534
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Analysis on Clinical Characteristics and Prognosis of 47 Patients with Extranodal NK/T Cell Lymphoma].
    Li QH; Yang P; Wang JJ; Dong F; Tian L; Wan W; Ke XY; Jing HM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Feb; 29(1):86-90. PubMed ID: 33554802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.